how many americans are on glp-1 medications According to the poll, the share of U.S. adults currently taking for weight loss has climbed to 11% in 2026, up from 3% just two years ago. 🔗⬇️ Poll: 1 in 8 Adults

Each peptide may be beneficial in its respective way

Post-Treatment: Patients experience minimal downtime with only slight redness or potential bruising

Off-Label Use: Some medications are prescribed off-label for weight loss: Semaglutide (Ozempic): FDA-approved for type 2 diabetes (not weight loss) Identical to Wegovy but different indication Commonly prescribed off-label for weight loss Same effectiveness as Wegovy Tirzepatide (Mounjaro): FDA-approved for type 2 diabetes (not weight loss) Identical to Zepbound but different indication Prescribed off-label for weight loss before Zepbound approval Same effectiveness as Zepbound Metformin: Diabetes medication sometimes used for weight loss Produces only 1-3% weight loss Not FDA-approved for weight loss Generally not recommended as primary weight loss medication The Current State of Weight Loss Medication: Clear Winners: GLP-1 receptor agonists (especially tirzepatide and semaglutide) have become the gold standard for medical weight loss, producing results previously unattainable with medication alone

Final Takeaway GLP-1s are powerful tools, but theyre not magic bullets